Keyword: Regeneron Pharmaceuticals
Most top R&D executives from across biopharma are earning around $7 million a year.
1. George Yancopoulos, Regeneron
The top research and development executives from across biopharma are certainly not looking down the back of the sofa for change; most are earning around $7 million a year. But then the job is tough, and arguably just as important as the top CEO job, given how much companies rely on the strength of their R&D.
The efficacy results suggest the experimental oral therapy, abrocitinib, has a shot at challenging the blockbuster biologic incumbent.
The cash will push a treatment for non-Hodgkin lymphoma into the clinic and support the development of Adicet’s gamma delta T-cell platform.
Pfizer’s JAK inhibitor cleared patients’ skin and improved atopic dermatitis symptoms in a second phase 3 study.
Opthea tested its drug in combination with Lucentis, finding that the combo bested Lucentis alone at improving vision and reducing scarring in the retina.
Medicines Company showed its siRNA inclisiran has a clean safety profile and is as effective as incumbent drugs sold by Amgen, Regeneron and Sanofi.
Regeneron unveiled new data showing its latest cholesterol med cut “bad” cholesterol levels in half in patients with stubbornly high cholesterol.
Investigators ended a study testing Ebola treatments from Gilead, Regeneron and the NIH because the latter two drugs beat ZMapp.